Literature DB >> 21352202

Immunomodulatory properties and therapeutic application of mesenchymal stem cells.

M Shi1, Z-W Liu, F-S Wang.   

Abstract

Mesenchymal stem cells (MSCs) are multi-potent progenitor cells that are isolated from the bone marrow and several adult organs and tissues. These cells possess remarkable immunosuppressive properties and can inhibit the proliferation and function of the major immune cell populations, including T cells, B cells and natural killer (NK) cells; modulate the activities of dendritic cells (DCs); and induce regulatory T cells both in vivo and in vitro. These unique properties make MSCs ideal candidates for clinical application as immunosuppressants. The immunomodulatory effect of MSCs is mediated by a non-specific anti-proliferative action of these cells, which is dependent on cell-cell contact or secreted soluble factors such as indoleamine 2,3-dioxygenase (IDO), prostaglandin E(2) (PGE(2) ), nitric oxide (NO), histocompatibility leucocyte antigen-G (HLA-G), transforming growth factor (TGF)-β, interferon (IFN)-γ and interleukin (IL)-1β. Considerable progress has been obtained in preclinical studies on MSCs, including those on their ability to activate allogeneic cells. This review examines the current understanding of the immunomodulatory properties of MSCs and its therapeutic implication for immune-mediated diseases and transplant rejection.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Year:  2011        PMID: 21352202      PMCID: PMC3074211          DOI: 10.1111/j.1365-2249.2011.04327.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  71 in total

1.  Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle.

Authors:  Rajesh Ramasamy; Henrietta Fazekasova; Eric W-F Lam; Inês Soeiro; Giovanna Lombardi; Francesco Dazzi
Journal:  Transplantation       Date:  2007-01-15       Impact factor: 4.939

2.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

Review 3.  Immunomodulation by mesenchymal stem cells and clinical experience.

Authors:  K Le Blanc; O Ringdén
Journal:  J Intern Med       Date:  2007-11       Impact factor: 8.989

4.  Mesenchymal stem cells for graft-versus-host disease: a double edged sword?

Authors:  F Vianello; F Dazzi
Journal:  Leukemia       Date:  2008-03       Impact factor: 11.528

5.  Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells.

Authors:  Kazuya Sato; Katsutoshi Ozaki; Iekuni Oh; Akiko Meguro; Keiko Hatanaka; Tadashi Nagai; Kazuo Muroi; Keiya Ozawa
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

6.  Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells.

Authors:  K English; J M Ryan; L Tobin; M J Murphy; F P Barry; B P Mahon
Journal:  Clin Exp Immunol       Date:  2009-02-03       Impact factor: 4.330

7.  Donor-derived mesenchymal stem cells remain present and functional in the transplanted human heart.

Authors:  M J Hoogduijn; M J Crop; A M A Peeters; S S Korevaar; M Eijken; J J Drabbels; D L Roelen; A P M M Maat; A H M M Balk; W Weimar; C C Baan
Journal:  Am J Transplant       Date:  2008-10-31       Impact factor: 8.086

8.  Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells.

Authors:  J M Ryan; F Barry; J M Murphy; B P Mahon
Journal:  Clin Exp Immunol       Date:  2007-05-22       Impact factor: 4.330

9.  The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study.

Authors:  H Ning; F Yang; M Jiang; L Hu; K Feng; J Zhang; Z Yu; B Li; C Xu; Y Li; J Wang; J Hu; X Lou; H Chen
Journal:  Leukemia       Date:  2008-01-10       Impact factor: 11.528

10.  Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells.

Authors:  Zohair Selmani; Abderrahim Naji; Ines Zidi; Benoit Favier; Emilie Gaiffe; Laurent Obert; Christophe Borg; Philippe Saas; Pierre Tiberghien; Nathalie Rouas-Freiss; Edgardo D Carosella; Frederic Deschaseaux
Journal:  Stem Cells       Date:  2007-10-11       Impact factor: 6.277

View more
  104 in total

Review 1.  Cell therapies for liver diseases.

Authors:  Yue Yu; James E Fisher; Joseph B Lillegard; Brian Rodysill; Bruce Amiot; Scott L Nyberg
Journal:  Liver Transpl       Date:  2012-01       Impact factor: 5.799

Review 2.  Cell-based approaches to the engineering of vascularized bone tissue.

Authors:  Rameshwar R Rao; Jan P Stegemann
Journal:  Cytotherapy       Date:  2013-08-31       Impact factor: 5.414

3.  Recent Patents Pertaining to Immune Modulation and Musculoskeletal Regeneration with Wharton's Jelly Cells.

Authors:  Limin Wang; Mark L Weiss; Michael S Detamore
Journal:  Recent Pat Regen Med       Date:  2013

4.  Reconstruction and validation of a constraint-based metabolic network model for bone marrow-derived mesenchymal stem cells.

Authors:  H Fouladiha; S-A Marashi; M A Shokrgozar
Journal:  Cell Prolif       Date:  2015-07-01       Impact factor: 6.831

Review 5.  Could cancer and infection be adverse effects of mesenchymal stromal cell therapy?

Authors:  Martha L Arango-Rodriguez; Fernando Ezquer; Marcelo Ezquer; Paulette Conget
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

6.  Broadening the translational immunology landscape.

Authors:  M Peakman
Journal:  Clin Exp Immunol       Date:  2012-12       Impact factor: 4.330

Review 7.  Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Authors:  Antonio Garcia-Gomez; Fermin Sanchez-Guijo; M Consuelo Del Cañizo; Jesus F San Miguel; Mercedes Garayoa
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

Review 8.  Mesenchymal stem cells as a potent cell source for articular cartilage regeneration.

Authors:  Mohamadreza Baghaban Eslaminejad; Elham Malakooty Poor
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

9.  Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response.

Authors:  Martha L Bustos; Luai Huleihel; Maria G Kapetanaki; Christian L Lino-Cardenas; Lyle Mroz; Bryon M Ellis; Bryan J McVerry; Thomas J Richards; Naftali Kaminski; Nayra Cerdenes; Ana L Mora; Mauricio Rojas
Journal:  Am J Respir Crit Care Med       Date:  2014-04-01       Impact factor: 21.405

Review 10.  Therapeutic Implications of Brain-Immune Interactions: Treatment in Translation.

Authors:  Andrew H Miller; Ebrahim Haroon; Jennifer C Felger
Journal:  Neuropsychopharmacology       Date:  2016-08-24       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.